EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Screening for Latent Tuberculosis Infection in Adults

Daniel E Jonas, Sean R Riley, Lindsey C Lee, Cory P Coffey, Shu-Hua Wang, Gary N Asher, Anne M Berry, Niketa Williams, Casey Balio, Christiane E Voisin, Leila C Kahwati

JAMA · 2023

DOI: 10.1001/jama.2023.3954 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JAMA, 2023. Verfasst von Daniel E Jonas und 10 weiteren Autor:innen. Beteiligte Einrichtung: RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park. Hauptthemen laut MEDLINE: Latent Tuberculosis, Mass Screening. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 143 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Latent tuberculosis infection (LTBI) can progress to active tuberculosis disease, causing morbidity and mortality.

Objective

To review the evidence on benefits and harms of screening for and treatment of LTBI in adults to inform the US Preventive Services Task Force (USPSTF). Data Sources PubMed/MEDLINE, Cochrane Library, and trial registries through December 3, 2021; references; experts; literature surveillance through January 20, 2023. Study Selection English-language studies of LTBI screening, LTBI treatment, or accuracy of the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). Studies of LTBI screening and treatment for public health surveillance or disease management were excluded. Data Extraction and Synthesis Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings; meta-analyses conducted when a sufficient number of similar studies were available. Main Outcomes and Measures Screening test accuracy; development of active tuberculosis disease, transmission, quality of life, mortality, and harms.

Results

A total of 113 publications were included (112 studies; N = 69 009). No studies directly evaluated the benefits and harms of screening. Pooled estimates for sensitivity of the TST were 0.80 (95% CI, 0.74-0.87) at the 5-mm induration threshold, 0.81 (95% CI, 0.76-0.87) at the 10-mm threshold, and 0.60 (95% CI, 0.46-0.74) at the 15-mm threshold. Pooled estimates for sensitivity of IGRA tests ranged from 0.81 (95% CI, 0.79-0.84) to 0.90 (95% CI, 0.87-0.92). Pooled estimates for specificity of screening tests ranged from 0.95 to 0.99. For treatment of LTBI, a large (n = 27 830), good-quality randomized clinical trial found a relative risk (RR) for progression to active tuberculosis at 5 years of 0.35 (95% CI, 0.24-0.52) for 24 weeks of isoniazid compared with placebo (number needed to treat, 112) and an increase in hepatotoxicity (RR, 4.59 [95% CI, 2.03-10.39]; number needed to harm, 279). A previously published meta-analysis reported that multiple regimens were efficacious compared with placebo or no treatment. Meta-analysis found greater risk for hepatotoxicity with isoniazid than with rifampin (pooled RR, 4.22 [95% CI, 2.21-8.06]; n = 7339). Conclusions and Relevance No studies directly evaluated the benefits and harms of screening for LTBI compared with no screening. TST and IGRAs were moderately sensitive and highly specific. Treatment of LTBI with recommended regimens reduced the risk of progression to active tuberculosis. Isoniazid was associated with higher rates of hepatotoxicity than placebo or rifampin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Latent TuberculosisMass ScreeningAdultHumansChemical and Drug Induced Liver InjuryIsoniazidQuality of LifeRandomized Controlled Trials as TopicRifampinUnited StatesAntitubercular AgentsPractice Guidelines as Topic

Substanzen

IsoniazidRifampinAntitubercular Agents

Autor:innen und Institutionen

  • RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park.
  • Department of Internal Medicine, The Ohio State University College of Medicine, Columbus.
  • Global One Health Initiative, The Ohio State University, Columbus.
  • Department of Family Medicine, University of North Carolina at Chapel Hill.
  • Department of Family Medicine and Community Health, Duke University, Durham, North Carolina.
  • North Carolina Department of Health and Human Services, Division of Public Health, Raleigh.

Zitieren

APA

Jonas, D. E., Riley, S. R., Lee, L. C., Coffey, C. P., Wang, S. H., Asher, G. N., Berry, A. M., Williams, N., Balio, C., Voisin, C. E., & Kahwati, L. C. (2023). Screening for Latent Tuberculosis Infection in Adults. JAMA. https://doi.org/10.1001/jama.2023.3954

Vancouver

Jonas DE, Riley SR, Lee LC, Coffey CP, Wang SH, Asher GN, et al. Screening for Latent Tuberculosis Infection in Adults. JAMA. 2023. doi:10.1001/jama.2023.3954

BibTeX
@article{Jonas2023,
  author = {Jonas, Daniel E and Riley, Sean R and Lee, Lindsey C and Coffey, Cory P and Wang, Shu-Hua and Asher, Gary N and Berry, Anne M and Williams, Niketa and Balio, Casey and Voisin, Christiane E and Kahwati, Leila C},
  title = {Screening for Latent Tuberculosis Infection in Adults},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2023.3954}
}
Kostenlos starten →